Literature DB >> 6884701

Antitumor effect and metabolic activation of cyclophosphamide and 4-hydroperoxycyclophosphamide in the human breast carcinoma (MX-1)-nude mouse system.

T Kubota, Y Hanatani, K Tsuyuki, M Nakada, K Ishibiki, O Abe, T Kamataki, R Kato.   

Abstract

The effects of cyclophosphamide (CPA) and its active form, 4-hydroperoxy-CPA, against human breast carcinoma transplanted into nude mice (BALB/c nu/nu) were evaluated in terms of the decreases of hepatic drug-metabolizing enzymes in nude mice. A human breast carcinoma, MX-1, was implanted into the subcutaneous tissue of nude mice and a drug was administered intravenously once at a dose of 0.05, 0.1 or 0.15 mmol/kg, 1 or 3 weeks after tumor inoculation. 4-Hydroperoxy-CPA was more effective than CPA as regards inhibition of tumor growth, and the difference in effect was greater when the drugs were administered 3 weeks after tumor inoculation. The activity of CPA was depressed by the decrease of the hepatic drug-metabolizing enzymes in proportion to the tumor-bearing period. Therefore, the effects of masked derivatives of CPA may correlate with the changes in drug-metabolizing activities of tumor-bearing mice. The human tumor xenografts-nude mice system is considered to be suitable for chemosensitivity tests with masked compounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6884701

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  3 in total

Review 1.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Combined cytotoxic and endocrine therapy for human breast carcinoma (Br-10) serially transplanted into nude mice.

Authors:  T Kubota; K Kubouchi; J Koh; F Asanuma; K Enomoto; K Ishibiki; O Abe
Journal:  Jpn J Surg       Date:  1984-01

3.  A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.

Authors:  K Satoh; N Kan; T Okino; M Nakanishi; K Mise; Y Teramura; S Yamasaki; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.